Y0002224

Sorafenib tosilate

CRS, European Pharmacopoeia (EP) Reference Standard

• Sinônimo(s): Sorafenib tosylate, 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate, BAY 43-9006 tosylate salt, BAY43-9006 tosylate salt, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, 4-methylbenzenesulfonate
• Fórmula empírica (Notação de Hill): C₂₁H₁₆ClF₃N₄O₃·C₇H₈SO₃
• Número CAS: 475207-59-1
• Peso molecular: 637.03
• Número MDL: MFCD08235032
• Código UNSPSC: 41116107
• NACRES: NA.24

Propriedades

• família API: sorafenib
• fabricante/nome comercial: EDQM
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: FC(F)(F)c2c(ccc(c2)NC(=O)Nc3ccc(cc3)Oc4cc([n+H]cc4)C(=O)NC)Cl.[S](=O)(=O)([O-])c1ccc(cc1)C
• InChI: 1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
• chave InChI: IVDHYUQIDRJSTI-UHFFFAOYSA-N

Descrição

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Sorafenib tosilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Orally active kinase inhibitor that exerts anticancer efficacy via targeting Raf-1 (c-Raf), b-Raf, VEGFR-2 (Flk-1, KDR), VEGFR-3, PDGFR-β, Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Tosylate salt of the orally active kinase inhibitor Sorafenib (BAY 43-9006) that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Informações de segurança

• Pictogramas: GHS08,GHS09
• Palavra indicadora: Danger
• Frases de perigo: H360FD,H362,H372,H410
• Declarações de precaução: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Classificações de perigo: Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
• Código de classe de armazenamento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable